MedTrace Logo

Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus

NCT03509701 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2018-08-29

No results posted yet for this study

Summary

Among patients with thunderclap headache who were admitted to the four participating hospitals, who has diffuse segmental vasoconstriction on CT angiography or MR angiography will be eligible for the study. Participants who meet the definition of RCVS will be enrolled as the case-patients and others will be enrolled as control-patients. The RCVS group will be defined when two or more neurologists agree by the clinical features and angiographic findings. The result of tests for varicella zoster virus titer will not be opened to neurologists until the end of the study. For case and control patients, tests for varicella zoster virus infection are (1) Pre-existing virological markers (ex. VZV-IgG, IgM, and VZV PCR in CSF or Skin lesion if present) (2) VZV-specific cell mediated immune response (CMI) at the time of admission and one month later (3) VZV in blood measured by quantitative test of viral load with real-time PCR and digital PCR for latent viral load (4) Quantitative test of viral load with real-time PCR in saliva at time of admission and one month later. Reactivation or infection of VZV of patients with RCVS and controls will be compared.

Conditions

  • Reversible Cerebral Vasoconstriction Syndrome
  • Varicella-zoster Virus Infection

Interventions

DIAGNOSTIC_TEST

VZV-specific antibody response from blood

Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva

Sponsors & Collaborators

  • Hanyang University

    collaborator OTHER

  • Eulji University Hospital

    collaborator OTHER

  • Kangbuk Samsung Hospital

    collaborator OTHER

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Sung-Han Kim, MD.Phd · Asan Medical Center

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509701 on ClinicalTrials.gov